Bladder Cancer News and Research

Latest Bladder Cancer News and Research

Parasitic flatworm rejuvenates its skin to survive in human bloodstream

A parasitic flatworm that infects hundreds of millions of people in the developing world is able to survive in the bloodstream for decades by constantly renewing its skin - a mechanism that could inform potential new treatments against infection.

23 Mar 2016

New subtype of bladder cancer shares molecular signatures with breast cancer

Bladder cancer is the fourth most common cancer among men in the United States. While low-grade tumors have a very favorable prognosis, muscle-invasive and metastatic tumors have poorer survival rates.

17 Mar 2016

Experimental drug improves survival rate of majority of lung cancer patients compared to standard chemotherapy

In global clinical trials, patients with advanced metastatic lung cancer who were treated with a targeted immunotherapy drug lived significantly longer and with fewer side effects than those who received standard second-line chemotherapy, according to a new Kaiser Permanente study published today in the journal The Lancet.

15 Mar 2016

Latest and final review of health problems related to Agent Orange exposure during Vietnam War

The latest and final in a series of congressionally mandated biennial reviews of the evidence of health problems that may be linked to exposure to Agent Orange and other herbicides used during the Vietnam War changed the categorization of health outcomes for bladder cancer, hypothyroidism, and spina bifida and clarified the breadth of the previous finding for Parkinson's disease.

11 Mar 2016

VTE patients tend to die earlier from bladder cancer

In a study of 3879 patients who underwent radical cystectomy to treat bladder cancer, 3.6% were diagnosed with a venous thromboembolism (VTE)—which occurs when a blood clot forms in a vein, potentially breaking loose and traveling to the lung—within 1 month of their surgical admission date.

8 Mar 2016

Johns Hopkins Greenberg Bladder Cancer Institute awards grants for 10 bladder cancer research projects

A study of obesity and related metabolic changes on bladder cancer incidence and deaths, and a plan to use stem cells to grow novel urinary tubes are among 10 research projects awarded funding by the Johns Hopkins Greenberg Bladder Cancer Institute.

7 Mar 2016

New article describes recent efforts made by researchers to classify bladder cancers

The ability to map the human genome has transformed how scientists and researchers classify various cancers. In the past, cancer cells were examined through a microscope and their appearance, often enhanced with dyes or other agents, was used to categorize the type of cancer.

22 Feb 2016

Liverpool researchers reach major milestone towards creating diagnostic test for prostate cancer

A research team from the University of Liverpool has reached an important milestone towards creating a urine diagnostic test for prostate cancer that could mean that invasive diagnostic procedures that men currently undergo eventually become a thing of the past.

12 Feb 2016

Scientists propose use of mathematical models to find better treatment for bladder cancer

MIPT scientists together with their colleagues from St. Petersburg and Israel have analyzed more than 500 previously published scientific articles and proposed their own approach to the choice of methods used for the treatment of one of the most common cancers.

11 Feb 2016

Colon cancer patients lacking CDX2 protein more likely to benefit from chemotherapy

Using a new computer science approach, researchers at University of California, San Diego School of Medicine, Columbia University and Stanford University discovered a distinctive molecular feature — a biomarker — that identified colon cancer patients who were most likely to remain disease-free up to five years after surgery.

22 Jan 2016

MDxHealth recognized with 2015 Global Frost & Sullivan Award for Technology Innovation

Based on its recent analysis of the prostate cancer diagnostics market, Frost & Sullivan recognizes MDxHealth with the 2015 Global Frost & Sullivan Award for Technology Innovation. To advance molecular diagnostic tests for urological cancers, MDxHealth supplemented its prostate cancer test, ConfirmMDx, with a urine-based "liquid-biopsy" test called SelectMDx.

21 Jan 2016

Researchers reveal totally new biological mechanism that underlies cancer

In a landmark study, researchers from the Broad Institute and Massachusetts General Hospital reveal a completely new biological mechanism that underlies cancer. By studying brain tumors that carry mutations in the isocitrate dehydrogenase (IDH) genes, the team uncovered some unusual changes in the instructions for how the genome folds up on itself.

13 Jan 2016

Patient's mental health prior to radical cystectomy can influence postoperative outcomes

A patient's mental health prior to surgery can influence postoperative outcomes. Removal of the bladder, or radical cystectomy (RC), is an effective treatment for locally advanced bladder cancer, but complications occur in as many as 66% of patients.

18 Dec 2015

Viralytics announces completion of $28 million placement

Viralytics Limited announces that it has completed a placement of 46,118,270 shares to international and domestic sophisticated or professional investors at an issue price of $0.615 per share to raise $28,362,736.

14 Dec 2015

Personalised peptide vaccination promising in bladder cancer

Metastatic bladder cancer patients who have progressed on first-line platinum-based chemotherapy could derive survival benefits from personalised peptide vaccination, according to phase II trial results.

27 Nov 2015

Novel immunotherapeutic approach could improve outcomes for patients with advanced bladder cancer

Noguchi explained that immunotherapy has emerged recently as a viable and attractive strategy for the treatment of advanced cancer.

18 Nov 2015

Viralytics enters into clinical trial collaboration agreement with MSD

Viralytics Limited announced today that it has entered into a clinical trial collaboration agreement through subsidiaries of Merck & Co., Inc., Kenilworth, New Jersey, U.S.A. (known as MSD outside the United States and Canada) to evaluate the combination of Viralytics' investigational cancer immunotherapy CAVATAK, with MSD's KEYTRUDA, an anti-PD-1 (programmed death receptor-1) therapy.

6 Nov 2015

Bladder Cancer News and Research

Latest Bladder Cancer News and Research

Parasitic flatworm rejuvenates its skin to survive in human bloodstream

New subtype of bladder cancer shares molecular signatures with breast cancer

Experimental drug improves survival rate of majority of lung cancer patients compared to standard chemotherapy

Latest and final review of health problems related to Agent Orange exposure during Vietnam War

VTE patients tend to die earlier from bladder cancer

Johns Hopkins Greenberg Bladder Cancer Institute awards grants for 10 bladder cancer research projects

New article describes recent efforts made by researchers to classify bladder cancers

Liverpool researchers reach major milestone towards creating diagnostic test for prostate cancer

Scientists propose use of mathematical models to find better treatment for bladder cancer

Colon cancer patients lacking CDX2 protein more likely to benefit from chemotherapy

MDxHealth recognized with 2015 Global Frost & Sullivan Award for Technology Innovation

Researchers reveal totally new biological mechanism that underlies cancer

Patient's mental health prior to radical cystectomy can influence postoperative outcomes

Viralytics announces completion of $28 million placement

Personalised peptide vaccination promising in bladder cancer

Novel immunotherapeutic approach could improve outcomes for patients with advanced bladder cancer

Viralytics enters into clinical trial collaboration agreement with MSD

Urinary biomarkers for bladder cancer diagnosis fall short of mark

Liposomal sizing and the Coulter principle: an interview with Professor Melvin E. Klegerman

Quest Diagnostics provides PD-L1 IHC 22C3 PharmDx test service for NSCLC patients

Industry Focus eBook - Oncology (1st Edition) eBook

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Extending the reach of Amperia™

Modular cleanrooms: Enhancing flexibility and compliance

Bladder Cancer News and Research

Latest Bladder Cancer News and Research

Industry Focus eBook - Oncology (1st Edition) eBook

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Extending the reach of Amperia™

Modular cleanrooms: Enhancing flexibility and compliance

Newsletters you may be interested in